La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Senseonics Holdings Gestione

Gestione criteri di controllo 2/4

Senseonics Holdings' Il CEO è Tim Goodnow, nominato in Dec2015, e ha un mandato di 8.67 anni. la retribuzione annua totale è $ 3.59M, composta da 17.1% di stipendio e 82.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.91% delle azioni della società, per un valore di $ 2.02M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.8 anni e 7.9 anni.

Informazioni chiave

Tim Goodnow

Amministratore delegato

US$3.6m

Compenso totale

Percentuale dello stipendio del CEO	17.1%
Mandato del CEO	8.8yrs
Proprietà del CEO	0.9%
Durata media del management	6.9yrs
Durata media del Consiglio di amministrazione	8yrs

Aggiornamenti recenti sulla gestione

Recent updates

How Much Is Senseonics Holdings' (NYSEMKT:SENS) CEO Getting Paid?

Dec 16

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tim Goodnow rispetto agli utili di Senseonics Holdings?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$80m
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$4m	US$613k	-US$60m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	US$57m
Dec 31 2022	US$4m	US$586k	US$142m
Sep 30 2022	n/a	n/a	US$215m
Jun 30 2022	n/a	n/a	US$318m
Mar 31 2022	n/a	n/a	US$34m
Dec 31 2021	US$3m	US$569k	-US$302m
Sep 30 2021	n/a	n/a	-US$489m
Jun 30 2021	n/a	n/a	-US$555m
Mar 31 2021	n/a	n/a	-US$382m
Dec 31 2020	US$3m	US$552k	-US$175m
Sep 30 2020	n/a	n/a	-US$109m
Jun 30 2020	n/a	n/a	-US$105m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$2m	US$536k	-US$116m
Sep 30 2019	n/a	n/a	-US$87m
Jun 30 2019	n/a	n/a	-US$100m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$2m	US$536k	-US$94m
Sep 30 2018	n/a	n/a	-US$103m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$520k	-US$59m

Compensazione vs Mercato: La retribuzione totale di Tim ($USD 3.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: La retribuzione di Tim è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Tim Goodnow (62 yo)

8.8yrs

Mandato

US$3,589,760

Compensazione

Dr. Timothy T. Goodnow, also known as Tim, Ph D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Goodnow	President	8.8yrs	US$3.59m	0.91% $ 1.7m
Mukul Jain	Chief Operating Officer	7.7yrs	US$1.56m	0.35% $ 658.1k
Kenneth Horton	General Counsel & Corporate Development Advisor	6.9yrs	US$1.31m	0.23% $ 423.2k
Francine Kaufman	Chief Medical Officer & Director	5.5yrs	Nessun dato	0.21% $ 387.4k
Frederick Sullivan	CFO, Secretary & Treasurer	2yrs	Nessun dato	0.10% $ 187.6k

6.9yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di SENS è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Goodnow	President	8.8yrs	US$3.59m	0.91% $ 1.7m
Francine Kaufman	Chief Medical Officer & Director	4.8yrs	Nessun dato	0.21% $ 387.4k
Douglas Roeder	Independent Non-Management Director	8.8yrs	US$174.75k	0.15% $ 282.2k
Edward Fiorentino	Independent Non-Management Director	8.8yrs	US$169.00k	0.16% $ 305.5k
Stephen DeFalco	Independent Chairman	8.8yrs	US$210.00k	0.31% $ 585.3k
Steven Edelman	Independent Non-Management Director	8yrs	US$164.00k	0.15% $ 280.7k
Douglas Prince	Independent Non-Management Director	8.8yrs	US$182.50k	0.12% $ 233.8k
Brian Hansen	Director	less than a year	Nessun dato	Nessun dato
Anthony Raab	Independent Non-Management Director	3.9yrs	US$152.50k	0.087% $ 162.3k
Sharon Larkin	Independent Non-Management Director	2.8yrs	US$159.00k	0.050% $ 93.8k
Koichiro Sato	Director	1.3yrs	Nessun dato	Nessun dato

8.0yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SENS sono considerati esperti (durata media dell'incarico 7.9 anni).

Senseonics Holdings Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Independent Non-Management Director recently bought US$162k worth of stock

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Senseonics Holdings, Inc. Announces CFO Transition

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Recent updates

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 22%

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought US$162k worth of stock

Price target decreased by 18% to US$1.67

New minor risk - Profitability

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 29%

Price target increased by 35% to US$2.75

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Consensus estimates of losses per share improve by 33%

Price target increased by 19% to US$2.50

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 33%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Investor sentiment improved over the past week

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$2.10

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Consensus revenue estimates increase by 23%

Price target increased to US$4.25

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Independent Non-Management Director notifies of intention to sell stock

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS misses analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Price target increased to US$4.17

President recently sold US$1.1m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Chief Medical Officer & Director notifies of intention to sell stock

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director exercised options and sold US$410k worth of stock

Independent Non-Management Director recently sold US$457k worth of stock

Consensus forecasts updated

Price target increased to US$2.58

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020)